Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer

C. William Helm, Robert E. Bristow, Shigeki Kusamura, Dario Baratti, Marcello Deraco

Research output: Contribution to journalArticlepeer-review

Abstract

Women with epithelial ovarian cancer (EOC) usually present with advanced disease and overall only just over half survive 5 years. Even following a complete response to front-line treatment two-thirds will recur, with a resultant dismal prognosis. We review and discuss the role of surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in EOC and present the results of the ovary consensus panel (OCP) convened for the 5th International Workshop on Peritoneal Surface Malignancy.

Original languageEnglish
Pages (from-to)283-290
Number of pages8
JournalJournal of Surgical Oncology
Volume98
Issue number4
DOIs
Publication statusPublished - Sep 15 2008

Keywords

  • Cytoreductive surgery
  • Epithelial ovarian cancer
  • Hyperthermia
  • Hyperthermic intraperitoneal chemotherapy (HIPEC)
  • Intraperitoneal chemotherapy
  • Loco-regional therapy

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint Dive into the research topics of 'Hyperthermic intraperitoneal chemotherapy with and without cytoreductive surgery for epithelial ovarian cancer'. Together they form a unique fingerprint.

Cite this